STOK NASDAQ
Stoke Therapeutics, Inc.
1W: +3.3%
1M: -16.0%
3M: -21.0%
YTD: -17.1%
1Y: +8.6%
3Y: +556.9%
5Y: -1.5%
$25.62
-0.39 (-1.50%)
Weekly Expected Move ±7.2%
$22
$24
$26
$27
$29
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (43)
Stoke Therapeutics, Inc. $STOK Shares Newly Acquired by Corient Private Wealth LP
Squarepoint Ops LLC Acquires Shares of 29,310 Stoke Therapeutics, Inc. $STOK
Bank of New York Mellon Corp Makes New Investment in Stoke Therapeutics, Inc. $STOK
Bank of America Corp DE Buys 336,931 Shares of Stoke Therapeutics, Inc. $STOK
Stoke Therapeutics (STOK) Q2 2026 Earnings Call Transcript
Stoke Therapeutics, Inc. $STOK Shares Acquired by Assenagon Asset Management S.A.
Dimensional Fund Advisors LP Buys 162,797 Shares of Stoke Therapeutics, Inc. $STOK
Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates
Ionis Begins Dosing in Phase I/II Dravet Syndrome Study
4 Biotech Stocks Investors Should Watch in 2026
Stoke Therapeutics (STOK) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Stoke Therapeutics, Inc. (STOK) Reports Q1 Results and Business Updates
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now?
Stoke outlines Q1 2027 rolling NDA start as EMPEROR enrollment targets June, backed by $411M cash balance
Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates
Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Lags Revenue Estimates
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Average Recommendation of “Moderate Buy” by Brokerages
The Credibility Filter Wall Street Uses to Sort Biotech Winners
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of “Moderate Buy” from Analysts
Stoke Therapeutics Stock Up 340% as Chair Sells $174K in Shares
Assenagon Asset Management S.A. Boosts Position in Stoke Therapeutics, Inc. $STOK
Stoke Therapeutics CMO Sells $457,000 in Stock Amid 300% Rally
FY2030 Earnings Estimate for STOK Issued By HC Wainwright
Stoke Therapeutics (NASDAQ:STOK) Shares Gap Down on Disappointing Earnings
Semtech To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Tuesday
Stoke Therapeutics (NASDAQ:STOK) Trading Down 6.6% After Insider Selling
Orchestra BioMed Holdings, Inc. (OBIO) Surpasses Q4 Earnings and Revenue Estimates
Vertex (VRTX) Moves 8.3% Higher: Will This Strength Last?
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Rating of “Moderate Buy” by Analysts
Dianthus Therapeutics, Inc. (DNTH) Stock Jumps 12.0%: Will It Continue to Soar?
Penserra Capital Management LLC Acquires New Position in Stoke Therapeutics, Inc. $STOK
Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Campbell & CO Investment Adviser LLC Acquires Shares of 30,418 Stoke Therapeutics, Inc. $STOK
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stoke Therapeutics: FDA Delay Doesn't Change Zorevunersen's Opportunity
Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Reviewing Cortex Pharmaceuticals (OTCMKTS:RSPI) & Stoke Therapeutics (NASDAQ:STOK)
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of “Buy” by Analysts
Assenagon Asset Management S.A. Has $21.16 Million Position in Stoke Therapeutics, Inc. $STOK
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Biotech Leader Stoke Therapeutics Offers Multiple Entries As Revenue Surges 117%
Stoke Therapeutics' Chief Medical Officer Sold Over 5,000 Shares in the Company. Should Shareholders Sell?
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of “Buy” from Analysts